Abstract:Uncovering the regulators of cellular aging will unravel the complexity of aging biology and identify potential therapeutic interventions to delay the onset and progress of chronic, aging-related diseases. In this work, we systematically compared genesets involved in regulating the lifespan of Saccharomyces cerevisiae (a powerful model organism to study the cellular aging of humans) and those with expression changes under rapamycin treatment. Among the functionally uncharacterized genes in the overlap set, YBR238C stood out as the only one downregulated by rapamycin and with an increased chronological and replicative lifespan upon deletion. We show that YBR238C and its paralog RMD9 oppositely affect mitochondria and aging. YBR238C deletion increases the cellular lifespan by enhancing mitochondrial function. Its overexpression accelerates cellular aging via mitochondrial dysfunction. We find that the phenotypic effect of YBR238C is largely explained by HAP4 - and RMD9 -dependent mechanisms. Furthermore, we find that genetic- or chemical-based induction of mitochondrial dysfunction increases TORC1 (Target of Rapamycin Complex 1) activity that, subsequently, accelerates cellular aging. Notably, TORC1 inhibition by rapamycin (or deletion of YBR238C ) improves the shortened lifespan under these mitochondrial dysfunction conditions in yeast and human cells. The growth of mutant cells (a proxy of TORC1 activity) with enhanced mitochondrial function is sensitive to rapamycin whereas the growth of defective mitochondrial mutants is largely resistant to rapamycin compared to wild type. Our findings demonstrate a feedback loop between TORC1 and mitochondria (the TO RC1– MI tochondria– TO RC1 (TOMITO) signaling process) that regulates cellular aging processes. Hereby, YBR238C is an effector of TORC1 modulating mitochondrial function.

The mTOR pathway is necessary for survival of mice with short telomeres

Hypothalamic Mtorc2 is Essential for Metabolic Health and Longevity

Mammalian target of rapamycin is essential for cardiomyocyte survival and heart development in mice.

A mild increase in nutrient signaling to mTORC1 in mice leads to parenchymal damage, myeloid inflammation and shortened lifespan

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

Longevity, stress response, and cancer in aging telomerase-deficient mice

mTOR and Aging: An Old Fashioned Dress

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

Characterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans

Targeting the biology of aging with mTOR inhibitors

Uncharacterized yeast gene YBR238C , an effector of TORC1 signaling in a mitochondrial feedback loop, accelerates cellular aging via HAP4 - and RMD9 -dependent mechanisms

Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice

TOR2 plays the central role in rapamycin-induced lifespan extension in budding yeast

Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice

Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin

The mTORC1-autophagy pathway is a target for senescent cell elimination

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

Myopathy Caused by Mammalian Target of Rapamycin Complex 1 (mtorc1) Inactivation is Not Reversed by Restoring Mitochondrial Function

Moderate Lifelong Overexpression of Tuberous Sclerosis Complex 1 (tsc1) Improves Health and Survival in Mice